Biogen's Friedreich's Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations
Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential.
Biogen Inc. (BIIB)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 1,585,572 | $216,969,673 | -2% | 0.19% |
| 2. | AQR Capital Management Cliff Asness | 1,368,842 | $187,257,678 | +154% | 0.19% |
| 3. | 998,400 | $136,621,056 | +319% | 0.03% | |
| 4. | Renaissance Technologies Jim Simons | 804,506 | $110,088,601 | -33% | 0.17% |
| 5. | Balyasny Asset Management Dmitry Balyasny | 786,219 | $107,586,208 | +1616% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $122.72 | 1,235 | $151,559.20 | 27,842 | 2025-05-02 | Filing | |
| $222.54 | 455 | $101,255.70 | 20,629 | 2024-02-15 | Filing | |
| $267.00 | 898 | $239,766.00 | 2,943 | 2021-02-09 | Filing | |
| $241.31 | 3,100 | $748,046.74 | 34,810 | 2020-11-30 | Filing | |
| $231.24 | 38,000 | $8,787,120.00 | 643,000 | 2019-05-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $126.25 | 3,806 | $480,507.50 | 5,427 | 2025-05-19 | Filing | |
| $150.02 | 8,760 | $1,314,141.91 | 11,318 | 2025-03-07 | Filing | |
| $157.21 | 110 | $17,293.10 | 5,426 | 2024-12-09 | Filing | |
| $204.22 | 431 | $88,018.82 | 5,316 | 2024-09-03 | Filing | |
| $213.09 | 93 | $19,817.37 | 4,886 | 2024-04-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,032,839 | $2,330,773,689 | 0.04% | |
| 2. | 15,943,259 | $2,181,675,561 | 1.8% | |
| 3. | 15,211,036 | $2,081,478,238 | 0.04% | |
| 4. | 7,396,910 | $1,012,193,164 | 0.04% | |
| 5. | 4,672,437 | $639,376,280 | 0.12% |
News See All
12 Best S&P 500 Stocks With Huge Upside Potential
Bankim Chadha, Deutsche Bank's chief global strategist, joined CNBC's 'The Exchange' on June 24 to express a cautionary view regarding further monetary policy movement despite recent positive inflation...
Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia.
Biogen Inc. (NASDAQ:BIIB) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Biogen Targets Rare Diseases, Eyes $800M Cost Cuts With ‘Fit for Growth’ Plan
Biogen Inc. (NASDAQ:BIIB) is one of the 15 best stocks to invest in for an 18 year old. On June 10, Biogen Inc.
Biogen, UCB Present Positive Phase 3 Results for Lupus Drug Candidate at EULAR 2025
Biogen Inc. (NASDAQ:BIIB) is one of the 11 most profitable NASDAQ stocks to buy now.
11 Most Profitable NASDAQ Stocks to Buy Now
Earlier on May 30, Siebert Financial CIO Mark Malek appeared on CNBC to discuss the tariff headwinds swirling around the markets and which sectors could then rise above the noise and continue to perform...
15 Best Stocks to Invest in for an 18 Year Old
The Bureau of Labor Statistics stated on June 11 that consumer prices increased less than anticipated in May given that President Donald Trump's tariffs had not yet had a noticeable effect on inflation...
Biogen Inc. (BIIB) Taps RNAi Therapy in City Therapeutics Deal
Biogen Inc. (NASDAQ:BIIB)’s recent partnership with City Therapeutics, Inc.
15 Small-Cap Healthcare Stocks Hedge Funds Are Buying
The U.S. healthcare sector has performed better in 2025 compared to the broader market. After two years of weak performance, the healthcare sector kicked off on a strong note in 2025.
Billionaire Hedge Funds
